# Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

> **NCT00477412** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 107 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00477412
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-03
- **Primary completion:** 2020-10-28
- **Final completion:** 2020-10-28
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2022-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00477412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00477412, "Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00477412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*